HemaQuest Pharmaceuticals Receives Orphan Drug Designations for Therapeutic to Treat Hemoglobin Disorders
November 04, 2008 09:00 ET
|
HemaQuest Pharmaceuticals
BOSTON, MA--(Marketwire - November 4, 2008) - HemaQuest Pharmaceuticals today announced that
the U.S. Food and Drug Administration (FDA) has awarded the company orphan
drug designations for sickle...
HemaQuest Announces Initiation of Phase I Clinical Trial of HQK-1001 to Treat Hemoglobin Disorders
January 17, 2008 09:00 ET
|
HemaQuest Pharmaceuticals
NEWTON, MA--(Marketwire - January 17, 2008) - HemaQuest Pharmaceuticals, which received its
first round of venture financing three months ago, today announced that the
U.S. Food and Drug...
HemaQuest Announces $20M Series A Financing for Anemia Drug Development
November 01, 2007 10:30 ET
|
HemaQuest Pharmaceuticals
NEWTON, MA--(Marketwire - November 1, 2007) - HemaQuest Pharmaceuticals, a new company
developing proprietary small molecule therapeutics to treat serious blood
disorders, today announced that it...